Hans-Peter Torsten Ekre

Cytoguide is a new biotech company devoted to the development of combined drugs that target receptors on cells in pathological tissues for medical purposes by linking drug candidates and registered drugs with known pharmacological effects to targeting receptor-binding protein partners. The development of receptor-targeted therapeutics will focus on the macrophage specific receptor CD163, the most abundant transport receptor on macrophages. The company has the IP right for existing CD163 targeting technology as well as strong scientific experience and know-how to exploit the use of this receptor for drug therapy. The combined drugs are aimed to improve the treatment of monocyte/macrophage-related diseases including autoimmune disease, leukemia and infectious diseases.

ProNoxis AB develops small-molecule drugs to treat chronic inflammation. The company was founded in 2009 and is headquartered in Lund, Sweden.

Bioneris is an specialized biotech innovation company and plans to work together with an industrial partner to commercialize the alpha trinositol molecule family. Bioneris has conducted a broad experimental series of pre-clinical trials that have demonstrated the effectiveness of alpha trinositol as a uniquely effective anti-cachexic agent. Bioneris will continue to develop the alpha trinositol molecule family and plans to develop additional applications for the molecule family. The company is also constantly expanding its extensive patent portfolio. Bioneris owns the exclusive rights to a large molecule family with an extensive clinical safety record and a large patent portfolio of approved patents. These factors contribute to the commercial potential of alpha trinositol and its derivatives. A common short coming of current cancer therapies is their safety profile, and Bioneris views the clinical safety record of alpha trinositol as an important advantage in its therapeutic and commercial application. Bioneris has conducted extensive pre-clinical cancer studies with a leading UK cancer research center. These experimental series have provided essential insights into the application and use of alpha trinositol in the treatment of cancer cachexia. Importantly, alpha trinositol is understood to have a therapeutic effect also in other indications besides cancer, such as restenosis, inflammation and arthritis. Bioneris has also elucidated the mode of action of alpha trinositol.

HBV Theranostica AB provides pharmaceutical research services. The company has developed a pretreatment marker for determining which patients with chronic hepatitis B virus infection are responders to a treatment with interferon-alpha. The company is headquartered in Solna, Sweden.

NovaSAID AB develops treatments for inflammation and pain in conditions such as rheumatoid arthritis. It discovers selective microsomal prostaglandin E synthase-1 (mPGES-1), and has also demonstrated its effect in animal models for pain and inflammation. The firm's approach is to prevent the pathological formation of prostaglandin E2 (PGE2) selectively, through the development of inhibitors of mPGES-1, the enzyme that is responsible for the formation of PGE2 during inflammation. Its mPGES-1 inhibition offers an approach for inhibiting pathological PGE2 production without adversely affecting other important prostanoids. The company was founded by Per-Johan Göte Jakobsson, Ralf Morgenstern, Bertil Samuelsson and Bengt Ingemar Samuelsson on October 26, 2004 and is headquartered in Solna, Sweden.

Palette Life Sciences AB operates as a pharmaceutical company. It specializes in developing products for local pain relief in obstetrics and gynecology. The company was founded by Berith Karlsson Tingåker, Gunvor Ekman-Ordeberg, Arne Folke Brodin and Lars Irestedt in 2009 and is headquartered in Solna, Sweden.